ONCC Certification Test Results Are Announced

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

PITTSBURGH-The Oncology Nursing Certification Corporation (ONCC) has announced the results of certification tests taken September 22, 2001. In a news release, the ONCC said that 154 registered nurses have earned their Advanced Oncology Certified Nurse (AOCN) credential. Of the 233 nurses who took the test, 66% earned a passing score, including 123 newly certified AOCNs and 31 renewals.

PITTSBURGH—The Oncology Nursing Certification Corporation (ONCC) has announced the results of certification tests taken September 22, 2001. In a news release, the ONCC said that 154 registered nurses have earned their Advanced Oncology Certified Nurse (AOCN) credential. Of the 233 nurses who took the test, 66% earned a passing score, including 123 newly certified AOCNs and 31 renewals.

Of nearly 3,000 nurses who took the Oncology Certified Nurse (OCN) test, 2,503 (85%) passed, including 1,409 who were newly certified and 1,094 who renewed their credential.

More than 300 registered nurses took the Certified Pediatric Oncology Nurse (CPON) examination, and 244 (77%) passed, 150 who were newly certified and 94 who renewed their CPON certification.

Articles in this issue
ODAC Sends Mixed Message on New Gliadel Wafer Indication
ONCC Certification Test Results Are Announced
Rituximab Ups Survival in Aggressive and Indolent NHL
Topotecan Used in Aggressive Front-Line Therapy for SCLC
Depsipeptide Shows Activity in T-Cell Lymphoma
FDG-PET Useful in Newly Diagnosed and Recurrent NSCLC
Adjuvant Anastrozole Superior to Tamoxifen in Huge ATAC Breast Cancer Trial
ODAC Backs Adding HER-2 DNA Test to Herceptin Package Insert
FDA and VA Plan Joint AIDS Study
Breast Conservation Increases With On-Site Radiation Unit
Washington State Hikes Cigarette Tax
Moffitt’s Diet Guidelines for Immunocompromised Patients
AMA Approves New CPT Code for Serum HER-2 Test
NCI Formalizes Role of Advocates
Better Prognosis for Outer Quadrant Breast Cancers
Related Videos
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Related Content
Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.

Pembrolizumab Maintenance Yields Enduring Responses in HER2– Breast Cancer

April 23rd 2024
Article

Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.

Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC

April 23rd 2024
Article

Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.

Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer

April 23rd 2024
Article

A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.

ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC

ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC

April 23rd 2024
Article

ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.